BRIGHTPATH BIOTHERAPEUTICS CO., LTD. BrightPath Biotherapeutics Co., Ltd. Stock
Equities
4594
JP3274140007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56 JPY | -3.45% |
|
-11.11% | -35.63% |
| Sales 2017 | 529M 3.42M | Sales 2018 | 354M 2.29M | Capitalization | 33.68B 218M |
|---|---|---|---|---|---|
| Net income 2017 | -1.11B -7.2M | Net income 2018 | -1.58B -10.2M | EV / Sales 2017 | 34.8 x |
| Net cash position 2017 | 4.95B 32.02M | Net cash position 2018 | 6.53B 42.22M | EV / Sales 2018 | 76.7 x |
| P/E ratio 2017 |
-19.2
x | P/E ratio 2018 |
-19.5
x | Employees | 42 |
| Yield 2017 * |
-
| Yield 2018 |
-
| Free-Float | 95.52% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -3.45% | ||
| 1 week | -11.11% | ||
| Current month | -16.42% | ||
| 1 month | -16.42% | ||
| 3 months | -34.88% | ||
| 6 months | -52.14% | ||
| Current year | -35.63% |
1 week
56.00
63.00
1 month
56.0068.00
Current year
56.0099.00
1 year
56.00171.00
3 years
56.00270.00
5 years
56.00389.00
10 years
56.002 229.00
| Managers | Title | Age | Since |
|---|---|---|---|
Kenichi Nagai
CEO | Chief Executive Officer | 53 | 08-12-31 |
| Director/Board Member | 55 | 16-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 77 | 15-05-31 | |
Akira Yamada
BRD | Director/Board Member | 67 | 03-04-30 |
Kenichi Nagai
CEO | Chief Executive Officer | 53 | 08-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 56 | -3.45% | 498 600 |
| 24-04-18 | 58 | +1.75% | 229,900 |
| 24-04-17 | 57 | 0.00% | 459,700 |
| 24-04-16 | 57 | -5.00% | 832,100 |
| 24-04-15 | 60 | -4.76% | 382,300 |
Delayed Quote Japan Exchange, April 19, 2024 at 02:00 am EDT
More quotes
BrightPath Biotherapeutics Co., Ltd. is a Japan-based company mainly engaged in the development of pharmaceutical products. The Company is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The Company also generates the revenues from license fees from the pharmaceutical companies.
Calendar
2024-05-09
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -35.63% | 25.56M | |
| -1.82% | 41.35B | |
| +42.78% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- 4594 Stock
